
Krystal Biotech (KRYS) Stock Forecast & Price Target
Krystal Biotech (KRYS) Analyst Ratings
Bulls say
Krystal Biotech Inc has demonstrated a solid financial performance with net revenue from its product Vyjuvek reaching $91.1 million in the most recent quarter, reflecting a 9% increase from the previous quarter, and total annual revenue of $290.5 million aligning with fiscal year projections. The company's innovative gene therapy platform, STAR-D, has shown promising preclinical data, particularly in improving survival rates for patients with difficult-to-treat conditions, indicating potential for future product development and market expansion. Furthermore, the company's strong financial position, characterized by disciplined operating expense management and the possibility of a share repurchase program, enhances its attractiveness as a growth-at-a-reasonable-price (GARP) investment opportunity.
Bears say
Krystal Biotech's stock outlook is negatively affected by a downward trend in new reimbursement approvals, with projections indicating a decline from 70 in 2Q24 to 50 in 4Q24, which raises concerns about revenue generation. Furthermore, the company faces significant risks related to the complexity and novelty of gene therapy manufacturing, potentially leading to delays in product development and commercialization. Compounding these issues are competitive pressures and challenges in patient recruitment for clinical trials, which may hinder the company's ability to achieve its financial targets.
This aggregate rating is based on analysts' research of Krystal Biotech and is not a guaranteed prediction by Public.com or investment advice.
Krystal Biotech (KRYS) Analyst Forecast & Price Prediction
Start investing in Krystal Biotech (KRYS)
Order type
Buy in
Order amount
Est. shares
0 shares